Thu. 18 Apr 2024, 7:14am ET
Benzinga
News
Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."